Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide

被引:105
作者
Sabichi, AL [1 ]
Hendricks, DT [1 ]
Bober, MA [1 ]
Birrer, MJ [1 ]
机构
[1] NCI, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA
关键词
D O I
10.1093/jnci/90.8.597
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4HPR) can inhibit the growth of tumor cells. Preliminary results from a clinical trial suggest that 4HPR may reduce ovarian cancer incidence. We examined the growth-inhibitory effects of 4HPR on gynecologic cancer cell lines in vitro and the role of retinoid receptors in modulating this effect. Methods: Twelve human gynecologic cancer cell lines (the ovarian cell lines-A224, AD10, UCI 101, UCI 107, SKOV3, 222, CP70, ML3B, and ML5; the cervical cell lines-HT3 and ME180; and the endometrial cell line-Hec 1A were tested for sensitivity to 4HPR (by assaying cell proliferation rates). Cel electrophoretic analysis of DNA fragmentation was used to measure programmed cell death (apoptosis), Specific retinoid receptor (retinoic acid receptor [RAR] and retinoid X receptor) messenger RNA (mRNA) levels were measured by northern blot hybridization, AD10 cells were stably transfected with human RAR beta complementary DNA, and the effect of 4HPR on cell proliferation was examined, Results: 4HPR inhibited the growth of all 12 cell lines, but to varying degrees; IC50 values (i.e., concentrations that inhibit proliferation by 50%) ranged from 0.3 to 9 mu M. Following 4HPR treatment, ovarian cancer cells that were sensitive to 4HPR (222, CP70, and UCI 101; IC50 <3 mu M) contained higher levels of RAR beta transcripts than more resistant cells (AD10, ME180, Hec 1A, and A224; IC50 greater than or equal to 3 mu M) (2.8-fold; two-sided P = .006), Anchorage-independent growth of transfected AD10 cells expressing high levels of RAR beta was totally abolished, even in the absence of 4HPR; transfectants expressing low levels of RAR beta exhibited lower levels of anchorage-independent growth and grew more slowly in the presence of 4HPR than control untransfected AD10 cells. Conclusion: 4HPR inhibited the proliferation of ovarian cancer cells lit vitro; RAR beta expression appeared to be associated with this effect.
引用
收藏
页码:597 / 605
页数:9
相关论文
共 34 条
[1]  
Ahn MJ, 1995, ONCOGENE, V11, P2357
[2]   THE TRANSACTIVATING DOMAIN OF THE C-JUN PROTO-ONCOPROTEIN IS REQUIRED FOR COTRANSFORMATION OF RAT EMBRYO CELLS [J].
ALANI, R ;
BROWN, P ;
BINETRUY, B ;
DOSAKA, H ;
ROSENBERG, RK ;
ANGEL, P ;
KARIN, M ;
BIRRER, MJ .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (12) :6286-6295
[3]  
COSTA A, 1994, CANCER RES, V54, pS2032
[4]  
DELIA D, 1993, CANCER RES, V53, P6036
[5]   CAN FENRETINIDE PROTECT WOMEN AGAINST OVARIAN-CANCER [J].
DEPALO, G ;
VERONESI, U ;
CAMERINI, T ;
FORMELLI, F ;
MASCOTTI, G ;
BONI, C ;
FOSSER, V ;
DELVECCHIO, M ;
CAMPA, T ;
COSTA, A ;
MARUBINI, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (02) :146-147
[6]   4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors [J].
Fanjul, AN ;
Delia, D ;
Pierotti, MA ;
Rideout, D ;
Qiu, J ;
Pfahl, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (37) :22441-22446
[7]  
FORMELLI F, 1993, CANCER RES, V53, P5374
[8]   5-YEAR ADMINISTRATION OF FENRETINIDE - PHARMACOKINETICS AND EFFECTS ON PLASMA RETINOL CONCENTRATIONS [J].
FORMELLI, F ;
CLERICI, M ;
CAMPA, T ;
DIMAURO, MG ;
MAGNI, A ;
MASCOTTI, G ;
MOGLIA, D ;
DEPALO, G ;
COSTA, A ;
VERONESI, U .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :2036-2042
[9]   Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide [J].
Formelli, F ;
Barua, AB ;
Olson, JA .
FASEB JOURNAL, 1996, 10 (09) :1014-1024
[10]  
Hendricks DT, 1997, CANCER RES, V57, P2112